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Abstract: Expression ofHLA-DRwhich isimmu-
ne response activation marker on T-cells and their sub-
populations (CD4+ and CD8+ lymphocytes) and num-
ber of CD4
+/CD25
+ cells with immune suppression
properties in blood of HIV/HCV coinfected patients
depending on HIV viral load, AIDS and receiving of
antiretroviral therapy werestudied. Itwasdetected that
HLA-DR expression on T-cells was significantly hig-
her in patients with detectable HIV viral load, AIDS,
andinpatients notreceiving antiretroviral therapy.An-
tiretroviraltherapyleadstosignificant reduction ofim-
mune system activation markers expression, though it
doesn’t allow to reach the level of healthy individuals.
Number of CD4
+/CD25
+ cells had inverse correlation
with activated CD3+ and CD3+CD8+ lymphocytes
and HIV viral load.
Key words: HIV, HCV, immunity activation, HLA-
-DR, CD4
+/CD25
+T-cells.
INTRODUCTION
Atpresentchronic activation ofimmunesystemis
the crucial aspect of HIV infection pathogenesis.
Hyperimmune response leads to synthesis of proin-
flammatory cytokines, increased production of new
HIVvirions, lossofcentral IScellular elements: CD4+
and CD8+ lymphocytes. IS activation is more signifi-
cantfactorthanCD4lymphocytes levelinsurvivalrate
prognosis of HIV infected patients (1, 2, 3).
There are various mechanisms, providing chronic
IS activation in HIV infection. One of the mechanisms
is associated with massive loss of CD4+ T-cells in the
intestinal lymphoid tissue of HIV infected patients,
which takes place from the first days of HIV infection.
This leads to disturbance of the intestinal wall barrier
properties, creates conditions for translocation into the
systemic circulation of intestinal flora microorgan-
isms, proinflammatory cytokines, lipopolysaccharides
produced by gram-negative intestinal bacterias (vigor-
ous stimulator of immune system cells), promoting ac-
tivation of immune system via innate pattern recogni-
tion (2, 4).
Another important mechanism of immune system
activation isinteraction ofHIV-1withT-cellsandmac-
rophages in the process of virus replication in an infec-
tedorganism.Itwasdetected thatHIVability toinduce
immune activation creates conditions for HIV replica-
tion in human cells, as far as productive HIV infection
can be realized only in activated human cells. It should
be added that various coinfections (bacterial, viral,
fungous, parasitic etc.) occurring in HIV infected pati-
ents were proved to be factors of immune system acti-
vation in HIVinfection. Anumber of studies show that
immunization of HIV infected patient may induce im-
mune system activation (2, 5).
Chronic immune system activation is associated
with some negative consequences for a patient: increa-
sed level of HIV in blood and tissues, high variability
of HIV, virus resistance to ART, increased ability of vi-
rus for transmission by sexual and transplacental rou-
tes,etc.Eventuallyimmunesystemactivationprovides
HIV infection progression and promotes unfavorable
disease prognosis (1, 6).
Cellular activation markers of the immune respon-
se are such molecules as HLA-DR, CD38+, CD71+ (6).
Membrane molecules HLA-DR, concerning to MCH–
–II class, are represented on antigen presenting cells
(dendritic cells, macrophages/monocytes, B-lympho-
cytes,vascularendothelium, etc.).Besides,fromthesi-
de of T-cells, participating in HLA-DR identification,
the connection with CD4-molecule is necessary as it
acts as a coreceptor for class II MHC molecules (1).
CD25 — is a receptor to one of the main T tropic
cyrokines — interleukin 2. CD127 low CD25 high is
subpopulation which represents FoxP3-expressing re-
gulatory CD4+ T-cells (7, 8).
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CD4+CD25+Tcells,inhibit activity ofeffectorT-cells
with CD4+CD25- phenotype. Number of CD4+CD25+
cells in blood of healthy donors makes up 0.7–5.5%
fromperipheralmononuclearcells.InHIVinfectedpa-
tients Treg cells induce suppression of HIV specific
and general cellular immune response (9, 10).
AIM OF THE RESEARCH
To detect content of T-cells, expressing HLA-DR
and content of CD4+/CD25+ T-cells in HIV/HCV
co-infected patients depending on HIV viral load,
AIDS, receiving of antiretroviral therapy.
MATERIALS AND METHODS
The patients included in the study were divided
into two groups. The 1st group included 51 patients
withHIV/HCVcoinfection, the2ndgroup consisted of
10patientswithHCVinfection. Todeterminetheclini-
cal stage of HIV infection WHO classification was
used (2006). Control group consisted of 16 healthy in-
dividuals (3 men and 13 women negative for the mark-
ers of viral hepatitis type B and C and HIV infection,
aged 32.5±15.1 years old on average). All patients we-
re tested for HBV and HCV serological markers using
ELISAkits. RNAload and HCV genotype was studied
using “Amplisens” kits(Russia).Thediagnosis ofHIV
infection was verified by detection of antibodies to
HIV using ELISA and immunoblot. Plasma viral load
(VL)ofRNAHIVweredetected usingAmpisensmon-
itor (Russia). Detectable level of RNA was defined as
500 copies/mL.
Clinical characteristic of patients included in the
study is given in Table 1.
As seen in Table 1, the age of patients in groups
didn’tdiffersignificantly,withmenprevalence. Paren-
teral way of HIV transmission due to intravenous drug
usewasdetectedin55%ofcasesingroup1andin10%
of cases in group 2. AIDS was established if level of
CD4+Tlymphocyteswaslessthan200cells/mkland/or
if patient had the fourth stage of HIVinfection accord-
ing to WHO classification, 2006.
Inthecurrentinvestigationthefollowingmonoclo-
nal antibodies were used (“Becton Dickenson”, USA):
1) CD3 (SK7, FITC) / CD16 (B73.1, PE) + CD56
(NCAM 16.2, PE) / CD45 (2D1, PerCP) / CD19
(SJ25C1, APC)
2) CD4 (SK3, FITC) /CD8 (SK1, PE) /CD3 (SK7,
PerCP)
3) HLA-DR (L243, APC)
4) CD4 (SK3, APC)
5) CD25 (M-A251, FITC).
The cells were analyzed using “FACSCalibur”
flow cytometer (“Becton Dickenson”, USA). Cell ac-
quisition and analysis were performed using “CellQu-
est” version 3.3 and “Weasel” version 2.9 software
(WEHI, Australia).
Statistical Analysis
Differences between groups were analyzed via
Kruskal-Wallis test and two-tailed unpaired nonpara-
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Index
group 1
HIV/HCV
n = 51
group 2
HCV
n = 10
Age, years 34.1 ± 5.9 40.3
Men. abs. (%) 39 (76.5) 7 (70.0)
Women. abs. (%) 12 (23.5) 3 (30.0)
IDU n (%) 28 (54.9) 1 (10.0)
1 genotype HCV. n (%) 17 (51.5)
* 7 (70.0)
Not 1 genotype HCV. n (%) 16 (48.5) 3 (30.0)
1 clinical category. n (%) 22 (43.1)
2 clinical category. n (%) 23 (45.1)
3 clinical category. n (%) 4 (7.8)
4 clinical category. n (%) 2 (3.9)
AIDS. n (%) 11 (23.5)
ART recipients. n (%) 17 (33.3)
Note:
*–p<0.05incomparison withthepatientsofgroup 2;test 
2;(IDU) —injectingdrug users;ART—antiretrovi-
ral therapy.
Table 1. Characteristics of patients in study groupsmetric Mann–Whitney’s test. The correlation between
variables was evaluated using Spearman rank coeffici-
ent (r). Avalue of p   0.05 was considered significant.
All calculations were performed using the Statistica
(StatSoft, USA) and StatPlus (AnalystSoft) software.
RESULTS
In group 1, 17 (33,3%) patients received ART. So,
the immunological parameters were compared in 2
subgroups of group 1. Patients receiving ART were in-
cludedingroup1Aandonesnotreceiving, ingroup1B
(table 2). ARTlasted from 6 months to 5 years. In most
patients ART scheme was represented by combination
of 2 nucleoside reverse transcriptase inhibitors and 1
non-nucleoside reverse transcriptase inhibitors, sche-
mes with protease inhibitors were received by 2 pati-
ents. The genotypes of HCV were detected in 33 pati-
ents in the group 1 and in all patients (n = 10) of the
group 2. The proportion of 1 genotype HCVwas signi-
ficantly higher in the patients of the 2nd group in com-
parison with the 1 st group.
As seen in Table 2, the highest expression of HLA-
-DR on T-cells was detected in 1B group patients
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Table 2. HLA-DR expression on T-cells in groups of patients
Parameter.
Median (ranges)
Control
n = 16
1A group
HIV/HCV
n = 17
1B group
HIV/HCV
n = 34
2 group
HCV
n = 10
HLA-DR
(%)
21.2
(15.6–36.3)
33.6
(21.1–71.5)
*,**** 46.8
(17.3–71.6)
*,**** 17.2
(11.3–42.5)
HLA-DR cells/ L
574.9
(225.9–1269.2)
629.2
(140.3–1227.6)
837.5
*,****
(224.1–1669.7)
379.0
(120.5–1534.3)
CD3+/HLA-DR
(%)
8.6
(2.2–18.7)
19.5
(12.0–67.6)
*,**** 33.9
(10.8–63.8)
*,**** 7.7
(4.3–22.73)
CD3+
/HLA-DR cells/ L
176.8
(60.9–652.8)
387.7
(74.3–1159.8)
*,***,**** 585.0
(174.1–1626.5)
*,**** 138.8
(77.2–796.6)
CD4+/HLA-DR
(%)
5.0
(2.9–9.9)
3.4
(1.9–6.4)
*,***,**** 4.1
(1.6–10.0)
* 3.7
(2.4–9.1)
CD4+
/HLA-DR cells/ L
101.5
(64.5–345.4)
55.8
(29.0–146.7)
* 72.6
(10.0 – 274.5)
* 81.8
(29.0–186.1)
CD8+/HLA-DR
(%)
5.4
(2.3–17.0)
23.0
(11.0–59.2)
*,**** 31.7
(12.8–60.6)
*,**** 6.7
(3.6–18.4)
CD8+
/HLA-DR cells/ L
114.7
(63.9–577.9)
366.4
(100.0–1015.4)
*,***,**** 518.9
(173.3–1655.3)
*,**** 124.0
(62.8–664.7)
Note:
*–p<0.05incomparisonwithcontrol;
**–p<0.05incomparisonwith1Agrouppatients;
***–p<0.05incompa-
rison with 1B group patients;
**** – p<0.05 in comparison with 2 group patients; Mann-Whitney test.
Parameter.
Median (ranges)
Control
n = 16
1A group
HIV/HCV
n = 17
1B group
HIV/HCV
n = 34
2 group
HCV
n = 10
CD25+
(%)
5.5
(3.5–8.5)
3.6
(1.8–8.0)
* 3.8
(0.5–9.5)
* 5.1
(2.8–14.0)
CD25+
cells/ L
128.3
(54.8–243.1)
49.6
(19.9–187.1)
*,**** 68.9
(7.6–260.5)
* 108.8
(35.3–170.2)
CD4+/CD25+
(%)
3.6
(2.2–6.0)
2.0
(1.1–4.1)
*,**** 1.8
(0.3–6.7)
*,**** 3.9
(1.4–8.1)
CD4+/CD25+
cells/ L
87.8
(40.9–162.1)
31.6
(11.3–95.0)
*,**** 34.7
(1.0–224.0
*,**** 87.7
(22.2–126.4)
Note:
* – p < 0.05 in comparison with control;
** – p < 0.05 in comparison with 1Agroup patients;
*** – p < 0.05 in com-
parison with 1B group patients;
**** – p < 0.05 in comparison with 2 group patients; Mann-Whitney test.
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Table 4. CD3+/HLA-DR (%) and CD8+/HLA-DR (%) correlations with other parameters
in HIV/HCV coinfected patients
Activated
T-cells Parameters 1A group
HIV/HCV. n = 17
1B group
HIV/HCV. n = 34
CD3+/
HLA-DR(%)
CD3+/CD4+ (%) NS R = – 0.80; p < 0.0001
CD3+/CD8+ (%) R = 0.5. p < 0.0001 R = 0.70; p < 0.0001
IRI NS R= – 0.79; p < 0.0001
CD8+/HLA-DR (%) R= 0.91. p < 0.0001 R= 0.95; p <0.0001
CD4+/CD25+ (%) NS R= – 0.73; p < 0.0001
HIV VL NS R = 0.53; p = 0.005
AIDS NS R = 0.42; p = 0.01
CD8+/
HLA-DR
CD3+/CD8+ (%) R = 0.52. p = 0.03 R = 0.71; p < 0.0001
IRI R = – 0.56. p = 0.02 R = – 0.82; p < 0.0001
CD3+/CD4+ (%) NS R = – 0.84; p < 0.0001
CD4+/CD25+ (%) NS R = – 0.70; p < 0.0001
AIDS NS R = 0.41; p = 0.02
HIV VL NS R = 0.56; p = 0.003
Note: R — Spearman’s rank correlation coefficient; NS — absence of significant differences (p > 0.05); IRI — immu-
neregulatory index (CD4+/CD8+)
Table 5. Parameters of HLA-DR expression in HIV/HCV co-infected patients
with detectable and undetectable HIV VL
Parameter.
Median (ranges)
HIV/HCV
VL < 500 cp/ml
n = 22
HIV/HCV
VL > 500 cp/ml
n = 22
P
HLA-DR (%) 33.0 (20.5–64.2) 50.7 (17.3–71.6) 0.02
HLA-DR cells/ L 595.8 (140.3–1305.6) 842.0 (224.1–1669.7) NS
CD3+/HLA-DR (%) 19.0 (12.0–52.0) 36.7 (10.8–63.8) 0.006
CD3+/HLA-DR cells/ L 373.0 (74.3–1023.3) 603.1 (174.1–1626.5) 0.04
CD4+/HLA-DR (%) 4.1 (1.9–10) 4.2 (1.6–6.7) NS
CD4+/HLA-DR cells/ L 62.6 (29.0–274.5) 67.2 (10.0–163.6) NS
CD8+/HLA-DR (%) 21.1 (11.0–48.8) 34.4 (12.9–60.3) 0.005
CD8+/HLA-DR cells/ L 384.5 (100.0–926.8) 582.3 (173.3–1655.3) 0.04
Note:
* — p, Mann-Whitney test.
Table 6. CD4+/CD25+ indices in HIV/HCV infected patients with detectable and undetectable HIV VL
Parameter.
Median (ranges)
HIV/HCV
VN < 500 cp/ml. n = 22
HIV/HCV
VN > 500 cp/ml. n = 22
P
CD25+ (%) 4.9 (1.8–9.5) 3.1 (0.5–6.7) 0.005
CD25+ cells/ L 82.0 (19.9–260.5) 48.9 (7.6–197.3) 0.05
CD4+/ CD25+ (%) 2.7 (0.7–6.7) 1.4 (0.3–3.2) 0.002
CD4+/ CD25+ cells/ L 38.8 (11.3–224.0) 29.8 (1.0–81.3) 0.02
Note: Mann-Whitney test.(HIV/HCV co-infection without ART), but percentage
of CD4+ lymphocytes and absolute value CD3+ and
CD8+T-cellsexpressedHLA-DRin1Bgroupweresig-
nificantly higher in comparison with 1Agroup patients,
receiving ART. At the same time indices of HLA-DR
expression on CD3+ and CD8+ T-cells in patients of 1A
and 1B groups were higher in comparison with the con-
trol group and group 2 (HCV infection). Percentage of
activated T-helpers in both groups of HIV infected pati-
ents was lower in comparison with control group, and
absolute content of activated T-helpers was lower in
comparison with the control group as well as group 2.
Percentage and absolute number ofCD4+/CD25+
Treg cells in studied groups are given in Table 3.
As seen in Table 3, CD25+ and CD4+/CD25+ in-
dices content didn’t significantly differ in patient gro-
ups receiving ART or not receiving ART. At the same
timesignificant differencesweredetected inbothpara-
meters with the control group. Besides, in both groups
with HIV/HCV coinfection percentage and absolute
value of CD4+/CD25+ cells were significantly lower
in comparison with HCV group.
A number of significant correlations of activated
CD3+ and CD8+ T-cells with other immunological pa-
rameters, viral serum load of HIV, AIDS in the groups
with HIV/HCV coinfected patients were detected (Ta-
ble 4).
AsseeninTable4,activatedCD3+andCD8+lym-
phocytes had opposite correlations with major T-cells
subpopulations(CD4+andCD8+).Directcorrelationof
activatedCD3+/HLA-DRandCD8+/HLA-DRcells in-
dices were observed with CD3+/CD8+ (%) in both
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Table 7. HLA-DR expression in patients with undetectable HIV VL (< 500 cp/ml.)
depending on receiving of antiretroviral therapy
Parameter.
Median (ranges)
1A group
HIV/HCV
n = 13
1B group
HIV/HCV
n=9
P
HLA-DR (%) 32.8 (21.1–64.2) 42.52 (20.5–63.2) NS
HLA-DR cells/ L 456.4 (140.3–1108.1) 910.3 (443.3–1305.6) 0.02
CD3+/HLA-DR (%) 18.3 (12.0–40.8) 30.4 (13.0–52.0) NS
CD3+/HLA-DR cells/ L 350.2 (74.3–765.0) 724.3 (287.8–1023.3) 0.02
CD4+/HLA-DR (%) 3.3 (1.9–6.4) 4.39 (3.0–10) 0.06
CD4+/HLA-DR cells/ L 41.1 (29.0–146.7) 113.4 (59.8–274.5) 0.003
CD8+/HLA-DR (%) 21.0 (11.0–48.3) 29.5 (12.8–48.8) NS
CD8+/HLA-DR cells/ L 327.4 (100.0–733.0) 511.8 (289.7–926.8) 0.02
Note:
* – p, Mann-Whitney test; patients didn’t receive (–) and received (+) ART.
Table 8. HLA-DR expression on T-cells and CD4+/CD25+ content in HIV/HCV coinfected patients
in absence and presence of AIDS
Parameter.
Median (ranges)
HIV/HCV
AIDS (–), n = 28
HIV/HCV
AIDS (+),n=6 P
*
HLA-DR (%) 44.8 (17.3–67.2) 62.6 (49.8–71.6) 0.006
HLA-DR cells/ L 843.9 (387.6–1669.7) 733.5 (224.1–1470.1) NS
CD3+/HLA-DR (%) 30.5 (10.8–59.8) 48.4 (34.7–63.8) 0.01
CD3+/HLA-DR. cells/ L 603.1 (243.7–1626.5) 562.1 (174.1–1023.8) NS
CD4+/HLA-DR (%) 4.1 (1.7–10.0) 4.1 (1.6–6.8) NS
CD4+/HLA-DR cells/ L 79.9 (48.4–274.5) 51.5 (10.0–75.7) 0.004
CD8+/HLA-DR (%) 30.0 (12.8–59.0) 44.1 (32.3–60.3) 0.02
CD8+/HLA-DR cells/ L 540.1 (283.7–1655.3) 512.9 (173.3–952.4) NS
CD4+/CD25+ (%) 2.3 (0.7–6.7) 1.0 (0.3–1.7) 0.004
CD4+/CD25+ cells/ L 43.4 (13.8–224.0) 10.6 (1.0–34.2) 0.002
Note:
* – p, Mann-Whitney test. NS – not significant (p > 0.05); presence (+) and absence (–) of AIDS stagegroups, while these indices had opposite correlation
with CD3+/CD4+ (%) in group 1B. In group 1B nega-
tive correlation between activated CD3+ and CD8+
and Treg CD4+/CD25+ (%)wasdetected aswell asdi-
rect correlation with presence of AIDS and HIV VL,
while in group 1A these correlations were absent. In
both groups with coinfection strong correlation was
detected between activated CD3+ and CD8+ lympho-
cytes.
HIV VLwas detected in 44 patients with HIV/HCV
coinfection: in 15 patients of 1A group and 29 of 1B.
Undetectable HIVVL(<500 cp/ml) was established in
13 patients of 1Agroup and in 9 patients from 1B gro-
up. Detectable HIV VL (>500 cp/ml) was established
in 2 patients of 1A group and in 20 patients from 1B
group.
As it is known HIV VL correlates with level of
HIV replication, which is one of the main mechanisms
of IR activation (6). In Table 5 indices of activation
markers expression in HIV/HCV co-infected patients
in group 1 are given according to level of HIV VL.
As seen in Table 5, percentage and absolute value
of activated CD3+ and CD8+ lymphocytes in patients
with detectable HIV VL were significantly lower than
in patients with undetectable HIV VL, which proves
correlation of T-cells activation with HIV replication
and increase of HIV VL. At the same time indices of
activated T-helpers didn’t significantly differ in the
compared groups.
ParametersofCD25expression onblood lympho-
cytes and CD4+/CD25+ content in HIV/HCV co-in-
fectedpatientsingroup1withdetectable andundetect-
able HIV VL are given in Table 6.
As seen in Table 6, CD25+ expression on blood
lymphocytes and CD4+/CD25+ cells in blood of pati-
ents with undetectable HIV VL was significantly hig-
her than in patients with detectable HIV VL.
It is known, that in HIV-infected patients before the
developmentofevidentimmunosuppressionHIVVLcan
stay at a low, undetectable level without ART for a long
time. In 13 patients from 1Agroup, receiving ART, HIV
VLwas at an undetectable level which indicates the pres-
ence of virological response on ART. At the same time in
1B group HIV undetectable level had been detected in 9
patients by the time of the research. Expression of
HLA-DR on T-cells of HIV/HCV coinfected patients
with undetectable HIV VL was compared in patient gro-
ups receiving and not receiving ART (Table 7).
As seen in Table 7, despite approximately equal
percentage of activated CD3+ and CD8+ T-cells, abso-
lute value of activated cells was significantly higher in
patients in group 1B, though HIV level was undetecta-
ble.NumberofCD4+/HLA-DRingroup1Awassigni-
ficantlylowerincomparisonwithpatientsingroup1B.
Atthe sametime in comparison ofactivation mar-
kers expression in patients with undetectable HIV VL
on ART with the control group significantly higher in-
dicesofactivatedCD3+andCD8+ofT-cellsandlower
CD4+/HLA-DR (p < 0,05) were detected in HIV/HCV
patients in group 1A. This fact indicates imbalance in
the immune system of HIV infected patients, despite
virological response (VR)on ART.Comparison ofthe-
se indices with HCV infection group showed signifi-
cantly higher parameters of CD3+/HLA-DR and
CD8+/HLA-DR (percentage and absolute value) in
HIV/HCV coinfection with undetectable HIV VL on
ART (p < 0,05).
Expression of CD25 on blood lymphocytes and
content of CD4+/CD25+ cells in HIV/HCVcoinfected
patients with undetectable HIVVLdepending on ART
receiving did not differ significantly (p > 0,05), unlike
the content of activated T-cells. These facts indicate
correlation ofCD4+/CD25+ cellswithHIVreplication
and,respectively,HIVVLmorecloselythanwithpara-
meters of immune system activation.
Activation of T-cell immune response in HIV in-
fection is more informative predictor of the disease
prognosis, than HIV replication level. Recent research
proved that SIV in natural conditions is a nonpathoge-
nic virus, despite high replication activity due to mini-
mal immunity activation (3). In this connection we
compared parameters of T-cell mediated immunity ac-
tivation inHIV/HCVcoinfected patients, notreceiving
ART with absence and presence of AIDS (Table 8).
As seen in Table 8, percentage of CD3+/HLA-DR
and CD3+CD8+/HLA-DR was higher in patients with
AIDS in comparison with patients without AIDS. Rela-
tive CD4+/HLA-DR indices did not significantly differ
in the compared groups but absolute CD4+/HLA-DR
index in AIDS was significantly lower. Percentage and
number of CD4+/ CD25+ cells was significantly lower
in AIDS, which was additionally proved by negative
correlation ofCD4+/ CD25+ index with HIVVL(Spe-
arman’s R correlation = –0,75; p < 0,0001).
DISCUSSION
Numerous researches displayed that ART reduces
IS activation by inhibiting of different HIV replication
stages(5,9).Theresultsofourresearchprovethisfact,
as a significant reduction of activated T-cells in
HIV/HCV coinfected patients receiving ART was de-
tected. It was proved that the patients not receiving
ART despite an undetectable HIV level had a higher
absolute level of HLA-DR activation markers expres-
sion on T-cells, than the patients with an undetectable
HIV VL receiving ART. This fact points that even at
undetectable HIVVLintheHIVinfectedpatientactive
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stressestheimportant roleofARTincontrolofHIVre-
plication.
At the same time virological response on ART in
the form of HIV VLreduction to an undetectable level
does not guarantee restoration of IS function. It is pro-
ved by increase of non-AIDS-related cancers frequ-
ency, such as non-Hodgkin lymphoma, papillomavirus
anorectal dysplasia andothermanifestations ofinflam-
matoryimmunereconstitution syndromeinpatientsre-
ceiving ART (1). In our research HLA-DR expression
on blood T-cells in patients receiving ARTwas consid-
erablyhigherincomparison withthecontrol groupand
HCVinfected patients. Continuing immune system ac-
tivation despite virological response on ART can be
explained by numerous mechanisms, including HIV
ability to “avoid” ART effect (6). Besides, presence of
various coinfections in HIV infected patients can sup-
port IS activation.
The disease progress and AIDS development was
associated with relative increase of HLA-DR expressi-
on on blood T-cells. At the same time absolute value of
theseindicesdidnotstatistically differinthecompared
groups, which can be associated with the development
of pancytopenia in AIDS.
It was detected, that binding of HIV with
CD4+CD25+ Treg cells increases their life span and
functional activity as well as induces redistribution of
these cells in human organism: migration from the pe-
ripheral blood and accumulation in the lymphoid tis-
sue, where the most intensive HIV replication occurs.
Due to CD4+CD25+ immunosuppressive activity in
the lymphoid tissue HIV-infected cells “avoid” immu-
ne control, which provides persistent HIV replication
and promotes disease progression (9, 10). One of the
immunosuppression mechanisms in HIV infection is
HIV ability to cause proliferation of CD4+/CD25+
T-cells by HIV specific antigenic stimulation. So,
CD4+/CD25+ T-cells are suppressors of immune re-
sponse in HIV-infected patients (8, 11).
In both HIV/HCV co-infection groups receiving
and not receiving ARTCD4+/ CD25+ content wassig-
nificantly lower in comparison with control group and
HCV group. Besides, opposite correlations between
activated CD3+ and CD8+ T-cells and Treg lympho-
cytes were received.
Thiscanbeassociatedwiththefactthatthemajor-
ityofCD4+/CD25+cellsinHIVinfectedpatientsislo-
calized in the lymph nodes, where the most intensive
HIVreplication,correlatingwithHIVVLoccurs(8,9).
In this connection HIV VL reduction due to inhibition
ofHIVreplication underARTisassociated withthein-
crease of CD4+/CD25+ cells in patients’ blood.
Therefore, in natural disease course immunity ac-
tivation in HIV infected patients is most evident at
AIDS stage and correlates with high level of HIV VL.
Reduction ofCD4+/CD25+lymphocytes content isas-
sociated with high HIVVL. So, in HIV/HCVco-infec-
ted patients at AIDS stage considerably lower level of
absolute and relative CD4+/CD25+ content was detec-
ted in blood in comparison with patients without
AIDS.
CONCLUSIONS
In natural disease course immunity activation in
HIV/HCV infected patients is more evident at AIDS
stage, as patients at AIDS stage had considerably hig-
her level of HLA-DR expression on blood CD3+ and
CD8+T-cells in comparison with patients without
AIDS. It was detected that HLA-DR expression on
T-cells and cytotoxic blood lymphocytes is consider-
ably higher in patients with the detectable HIVVL. Vi-
rological response on ART lead to significant reduc-
tion of immune system activation markers expression,
though it was significantly higher in comparison with
the level of healthy individuals. Reduction of
CD4+/CD25+ lymphocytes in blood is associated with
high HIV VL. In the patients with AIDS stage a lower
index of CD4+/CD25+ blood lymphocytes was detec-
ted compared to those patients without AIDS. Regula-
tory T-cells had an opposite correlation with content of
activated CD3+ and CD8+ lymphocytes and HIV VL.
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AKTIVACIJAT-]ELIJAU KRVI HIV/HCVKOINFICIRANIH PACIJENATA
Matsiyeuskaya V. Natallia, Vladimir M. Tsyrkunov
Grodno State Medical University, Grodno, Belarus
Us t u d i j ij ei s p i t i v a n ae k s p r e s i j aH L A - D Rr e c e p -
tora na T-}elijama i njihovim subpopulacijama
(CD4+ i CD8+ limfocitima), kao i broj CD4+/CD25+
}elija sa imunosupresivnim svojstvima, u krvi
HIV/HCVkoinficiranih pacijenata u zavisnosti od ni-
voa HIV virusa u serumu, AIDS-a i primanja antire-
trovirusne terapije. Otkriveno je da je ekspresija
HLA-DR na T-}elijama zna~ajno ve}a kod pacijenata
sa detektabilnim nivoom HIV u serumu, AIDS-om, i
kod pacijenata koji ne primaju antiretrovirusnu tera-
piju. Antiretrovirusna dovodi do zna~ajne redukcije
ekspresijemarkeraaktivacijeimunogsistema,iakose
me|utim ne dosti`e nivo kao kod zdravih osoba. Broj
CD4+/CD25+ }elija ima negativnu korelaciju sa akti-
viranim CD3+ i CD3+CD8+ limfocitima, kao i sa vi-
rusnim nivoom HIV u serumu.
Klju~ne re~i: HIV, HCV, aktivacija imunog siste-
ma, HLA-DR, CD4+/CD25+ T-}elija.
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